H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Therefore, new therapeutic or strategies already available for treatment of CDI have two goals: eradicating the infection, despite the continuation of concomitant therapy, and reducing the ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

In fact, C. diff infections often spring up because the bacteria take advantage of a weakened microbiome following treatment with antibiotics for other diseases. “Treatment of C. difficile ...

She led CDC activities to detect and prevent infections in healthcare settings ... and developing innovative microbiome therapeutics and treatments for inflammatory bowel disease (IBD).

But patients often go untreated for years — either because they don’t realize their infection is serious and requires treatment, or because they lose contact with the health system.

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Clostridium difficile infection (CDI) is considered to be the ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical ...